Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

10 Mar 2009 17:10

RNS Number : 6445O
Phytopharm PLC
10 March 2009
 



NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

This form is intended for use by an issuer to make a RIS notification required by DR 3.1.4R(1).

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. 

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. 

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. 

 

Please complete all relevant boxes in block capital letters.

1. Name of the issuer

PHYTOPHARM PLC

2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii)

(III) BOTH (I) AND (II)

3. Name of person discharging managerial responsibilities/director

DR PETER ROBIN BLOWER, NON-EXECUTIVE DIRECTOR

4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

AS 3 ABOVE

5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest

AS 3 ABOVE

6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 1 PENCE EACH

7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

AS 3 ABOVE

8 State the nature of the transaction

SHARES ACQUIRED

9. Number of shares, debentures or financial instruments relating to shares acquired

88,888

10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.09%

11. Number of shares, debentures or financial instruments relating to shares disposed

12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) 

13. Price per share or value of transaction

4.5 PENCE PER SHARE

14. Date and place of transaction

10 March 2009, LONDON

15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

118,682 - 0.13%

16. Date issuer informed of transaction

10 MARCH 2009

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17 Date of grant

18. Period during which or date on which it can be exercised

19. Total amount paid (if any) for grant of the option

20. Description of shares or debentures involved (class and number)

21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22. Total number of shares or debentures over which options held following notification

23. Any additional information

24. Name of contact and telephone number for queries

ZOE MCGOWAN 01480 437697

Name and signature of duly authorised officer of issuer responsible for making notification

ZOE MCGOWAN

Date of notification

10 MARCH 2009

END 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSJMMRTMMMBBAL
Date   Source Headline
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.